Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Procter & Gamble Health Limited (PGHL.NS)
INR6,867.00
-51.50 (-0.74%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Godrej One 400079
Mumbai, IN
Mumbai, IN
CEO
Milind Vasant Thatte
Website
pghealthindia.com
IPO
2002-07-01
ISIN INE199A01012
Also trades on
Bombay Stock Exchange · PGHL.BO (INR)
National Stock Exchange of India · PGHL.NS (INR)
Description
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR6,867.00
-51.50 (-0.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
27.6K
Beta
0.24
Float Shares
7.93M
Free Float %
47.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.01% | +15.03% | +22.73% | +28.05% | +9.65% | +10.03% | +9.52% | +20.88% | +5.26% | +764.03% | +1,971.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6,867.00
DCF (Unlevered)
16,537.47
+140.8%
DCF (Levered)
14,616.39
+112.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
23.58
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+15.6% ★ Q1'26: +19.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+30.3% ★ Q1'26: +54.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+20.9% ★ Q1'26: +44.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+32.0% ★ Q1'26: +36.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+93.9% ★ Q1'26: +108.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2000 actual |
Mar 2001 actual |
Mar 2002 actual |
Mar 2003 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.09B
est.
|
3.16B
est.
|
3.82B
est.
|
3.64B
est: 3.80B (-4.1%)
|
7.97B
est: 6.48B (+22.9%)
|
8.66B
est: 8.09B (+7.1%)
|
9.38B
est: 9.70B (-3.2%)
|
9.93B
est: 9.70B (+2.4%)
|
6.98B
est: 10.25B (-31.9%)
|
8.49B
est: 10.25B (-17.1%)
|
11.14B
est.
|
8.89B
est: 11.28B (-21.2%)
|
10.09B
est: 9.51B (+6.1%)
|
11.14B
est: 10.94B (+1.8%)
|
12.30B
est: 11.26B (+9.2%)
|
11.51B
est: 13.67B (-15.8%)
|
12.18B
est: 13.67B (-10.9%)
|
13.52B
13.52B – 13.52B
-1.1% YoY
|
15.00B
15.00B – 15.00B
+11.0% YoY
|
| EBITDA |
800.92M
est.
|
341.71M
est.
|
694.65M
est.
|
933.70M
est: 716.75M (+30.3%)
|
771.00M
est: 1.22B (-37.0%)
|
588.30M
est: 1.81B (-67.5%)
|
874.80M
est: 1.31B (-33.4%)
|
1.25B
est: 1.09B (+14.1%)
|
1.02B
est: 1.32B (-23.3%)
|
1.51B
est: 1.81B (-16.7%)
|
1.59B
est.
|
2.09B
est: 9.27B (-77.5%)
|
2.42B
est: 2.51B (-3.5%)
|
2.65B
est: 2.84B (-6.8%)
|
3.19B
est: 2.92B (+9.1%)
|
3.03B
est: 3.78B (-19.7%)
|
3.62B
est: 3.78B (-4.2%)
|
3.74B
3.74B – 3.74B
-1.1% YoY
|
4.15B
4.15B – 4.15B
+11.0% YoY
|
| EBIT |
739.11M
est.
|
257.89M
est.
|
581.39M
est.
|
837.60M
est: 550.12M (+52.3%)
|
671.50M
est: 939.98M (-28.6%)
|
462.90M
est: 1.21B (-61.6%)
|
641.90M
est: 737.28M (-12.9%)
|
1.00B
est: 511.36M (+95.6%)
|
754.60M
est: 641.34M (+17.7%)
|
1.26B
est: 1.01B (+24.5%)
|
510.93M
est.
|
1.89B
est: 1.25B (+51.4%)
|
2.17B
est: 2.07B (+5.0%)
|
2.43B
est: 2.62B (-7.5%)
|
2.96B
est: 2.70B (+9.7%)
|
2.79B
est: 3.53B (-20.8%)
|
3.43B
est: 3.53B (-2.7%)
|
3.49B
3.49B – 3.49B
-1.1% YoY
|
3.87B
3.87B – 3.87B
+11.0% YoY
|
| Net Income |
338.48M
est.
|
185.23M
est.
|
466.33M
est.
|
396.40M
est: 443.87M (-10.7%)
|
558.80M
est: 758.43M (-26.3%)
|
432.20M
est: 978.22M (-55.8%)
|
535.60M
est: 616.05M (-13.1%)
|
791.30M
est: 477.12M (+65.8%)
|
939.10M
est: 560.27M (+67.6%)
|
8.39B
est: 882.62M (+850.3%)
|
827.69M
est.
|
1.66B
est: 8.25B (-79.9%)
|
1.77B
est: 1.74B (+1.7%)
|
1.93B
est: 2.27B (-15.3%)
|
2.29B
est: 2.05B (+11.7%)
|
2.01B
est: 2.40B (-16.1%)
|
2.51B
est: 2.40B (+4.8%)
|
3.15B
3.15B – 3.15B
+31.3% YoY
|
3.58B
3.58B – 3.58B
+13.9% YoY
|
| SGA |
705.16M
est.
|
1.03B
est.
|
1.15B
est.
|
—
est: 1.04B (-100.0%)
|
2.65B
est: 1.77B (+49.1%)
|
1.89B
est: 1.70B (+11.1%)
|
2.11B
est: 1.83B (+14.8%)
|
2.35B
est: 3.68B (-36.3%)
|
2.08B
est: 3.79B (-45.2%)
|
2.43B
est: 4.49B (-46.0%)
|
1.89B
est.
|
2.47B
est: 2.59B (-4.7%)
|
2.43B
est: 2.17B (+11.7%)
|
2.78B
est: 2.50B (+11.0%)
|
2.81B
est: 2.57B (+9.3%)
|
2.68B
est: 2.47B (+8.7%)
|
2.33B
est: 2.47B (-5.4%)
|
2.44B
2.44B – 2.44B
-1.1% YoY
|
2.71B
2.71B – 2.71B
+11.0% YoY
|
| EPS |
20.39
est.
|
20.72
est.
|
29.20
est.
|
23.50
est: 32.68 (-28.1%)
|
33.66
est: 44.44 (-24.3%)
|
26.04
est: 41.82 (-37.7%)
|
32.27
est: 32.51 (-0.7%)
|
47.67
est: 32.51 (+46.6%)
|
36.77
est: 45.06 (-18.4%)
|
61.29
est: 45.06 (+36.0%)
|
48.19
est.
|
99.87
est: 90.63 (+10.2%)
|
106.51
est: 114.00 (-6.6%)
|
115.98
est: 136.90 (-15.3%)
|
138.24
est: 123.75 (+11.7%)
|
121.08
est: 144.40 (-16.1%)
|
151.33
est: 144.40 (+4.8%)
|
189.60
189.60 – 189.60
+31.3% YoY
|
215.90
215.90 – 215.90
+13.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
439.95M
OE per share TTM
26.51
Owner's Yield
0.42%
Maintenance CapEx ratio
6.95%
Maint CapEx / Avg PPE
12.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 8 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.04% | 307.3K | 0.65% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 82.4K | 0.44% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 40.1K | 0.56% |
| 4 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 965.6K | 0.07% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.01% | 479.6K | 0.29% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 429.8K | 0.39% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 287.5K | 0.28% |
| 8 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.00% | 4.8K | 0.09% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.37M
Shares Outstanding
16.60M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Milind Vasant Thatte | MD & Executive Director | 25M | male |
| Shashank Srowthy | Chief Financial Officer & Executive Director | 19M | male |
| Prachi Vichare | Assistant Company Secretary | — | female |
| Sanika Gokhale | Human Resource Leader | — | female |
| Vishal Naik | Director of Sales, Distributor Operations & Sales Stewardship Leader | — | male |
| Zeal Bhavin Rupani | Compliance Officer & Company Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PGHL.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
